Literature DB >> 9391160

Molecular determinants of tissue selectivity in estrogen receptor modulators.

T A Grese1, J P Sluka, H U Bryant, G J Cullinan, A L Glasebrook, C D Jones, K Matsumoto, A D Palkowitz, M Sato, J D Termine, M A Winter, N N Yang, J A Dodge.   

Abstract

Interaction of the estrogen receptor/ligand complex with a DNA estrogen response element is known to regulate gene transcription. In turn, specific conformations of the receptor-ligand complex have been postulated to influence unique subsets of estrogen-responsive genes resulting in differential modulation and, ultimately, tissue-selective outcomes. The estrogen receptor ligands raloxifene and tamoxifen have demonstrated such tissue-specific estrogen agonist/antagonist effects. Both agents antagonize the effects of estrogen on mammary tissue while mimicking the actions of estrogen on bone. However, tamoxifen induces significant stimulation of uterine tissue whereas raloxifene does not. We postulate that structural differences between raloxifene and tamoxifen may influence the conformations of their respective receptor/ligand complexes, thereby affecting which estrogen-responsive genes are modulated in various tissues. These structural differences are 4-fold: (A) the presence of phenolic hydroxyls, (B) different substituents on the basic amine, (C) incorporation of the stilbene moiety into a cyclic benzothiophene framework, and (D) the imposition of a carbonyl "hinge" between the basic amine-containing side chain and the olefin. A series of raloxifene analogs that separately exemplify each of these differences have been prepared and evaluated in a series of in vitro and in vivo assays. This strategy has resulted in the development of a pharmacophore model that attributes the differences in effects on the uterus between raloxifene and tamoxifen to a low-energy conformational preference imparting an orthogonal orientation of the basic side chain with respect to the stilbene plane. This three-dimensional array is dictated by a single carbon atom in the hinge region of raloxifene. These data indicate that differences in tissue selective actions among benzothiophene and triarylethylene estrogen receptor modulators can be ascribed to discrete ligand conformations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9391160      PMCID: PMC28440          DOI: 10.1073/pnas.94.25.14105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Non-isomerisable antiestrogens related to tamoxifen.

Authors:  R McCague; M Jarman; O T Leung; A B Foster; G Leclercq; S Stoessel
Journal:  J Steroid Biochem       Date:  1988-10       Impact factor: 4.292

2.  Novel antioestrogens without partial agonist activity.

Authors:  A E Wakeling; J Bowler
Journal:  J Steroid Biochem       Date:  1988-10       Impact factor: 4.292

3.  Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.

Authors:  A D Palkowitz; A L Glasebrook; K J Thrasher; K L Hauser; L L Short; D L Phillips; B S Muehl; M Sato; P K Shetler; G J Cullinan; T R Pell; H U Bryant
Journal:  J Med Chem       Date:  1997-05-09       Impact factor: 7.446

4.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.

Authors:  C D Jones; M G Jevnikar; A J Pike; M K Peters; L J Black; A R Thompson; J F Falcone; J A Clemens
Journal:  J Med Chem       Date:  1984-08       Impact factor: 7.446

5.  Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity.

Authors:  D W Robertson; J A Katzenellenbogen; J R Hayes; B S Katzenellenbogen
Journal:  J Med Chem       Date:  1982-02       Impact factor: 7.446

6.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Authors:  L J Black; M Sato; E R Rowley; D E Magee; A Bekele; D C Williams; G J Cullinan; R Bendele; R F Kauffman; W R Bensch
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

7.  Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain.

Authors:  J M Beekman; G F Allan; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Endocrinol       Date:  1993-10

8.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.

Authors:  P Webb; G N Lopez; R M Uht; P J Kushner
Journal:  Mol Endocrinol       Date:  1995-04

9.  Potential antifertility agents. 1. Substituted diaryl derivatives of benzo[b]thiophenes, benzo[b]furans, 1H-2-benzothiapyrans, and 2H-1-benzothiapyrans.

Authors:  R R Crenshaw; A T Jeffries; G M Luke; L C Cheney; G Bialy
Journal:  J Med Chem       Date:  1971-12       Impact factor: 7.446

10.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

View more
  38 in total

1.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

Authors:  L A Paige; D J Christensen; H Grøn; J D Norris; E B Gottlin; K M Padilla; C Y Chang; L M Ballas; P T Hamilton; D P McDonnell; D M Fowlkes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  Selective estrogen receptor modulators.

Authors:  Henry U Bryant
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 3.  Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells.

Authors:  Greg Nalbandian; Susan Kovats
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 4.  Bioactivation of Selective Estrogen Receptor Modulators (SERMs).

Authors:  Tamara S Dowers; Zhi-Hui Qin; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

5.  Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors:  Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

6.  Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain.

Authors:  Natalia Varlakhanova; Chelsea Snyder; Soumia Jose; Johnnie B Hahm; Martin L Privalsky
Journal:  Mol Cell Biol       Date:  2010-01-11       Impact factor: 4.272

7.  Parallel synthesis of a desketoraloxifene analogue library via iodocyclization/palladium-catalyzed coupling.

Authors:  Chul-Hee Cho; Dai-Il Jung; Benjamin Neuenswander; Richard C Larock
Journal:  ACS Comb Sci       Date:  2011-07-13       Impact factor: 3.784

Review 8.  Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

Authors:  Christa K Baumann; Monica Castiglione-Gertsch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

Review 10.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.